Cart
sales@molnova.com
p-Cresyl sulfate
CAS No. 3233-58-7
p-Cresyl sulfate( —— )
Catalog No. M24256 CAS No. 3233-58-7
The p-Cresol is a protein-bound uremic retention solute. Free p-Cresol was found to be a cardiovascular risk factor in non-diabetic hemodialysis patients.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 110 | In Stock |
|
| 10MG | 177 | In Stock |
|
| 25MG | 312 | In Stock |
|
| 50MG | 464 | In Stock |
|
| 100MG | 662 | In Stock |
|
| 500MG | 1332 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Namep-Cresyl sulfate
-
NoteResearch use only, not for human use.
-
Brief DescriptionThe p-Cresol is a protein-bound uremic retention solute. Free p-Cresol was found to be a cardiovascular risk factor in non-diabetic hemodialysis patients.
-
DescriptionThe p-Cresol is a protein-bound uremic retention solute. Free p-Cresol was found to be a cardiovascular risk factor in non-diabetic hemodialysis patients.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number3233-58-7
-
Formula Weight188.2
-
Molecular FormulaC7H8O4S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 250 mg/mL (1328.37 mM)
-
SMILESCC1=CC=C(OS(=O)(O)=O)C=C1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Meijers B K I, Bammens B, De Moor B, et al. Free p-cresol is associated with cardiovascular disease in hemodialysis patients. Kidney international, 2008, 73(10): 1174-1180.
molnova catalog
related products
-
JNJ 10191584 maleate
histamine H4 receptor silent antagonist
-
Thalidomide 4'-ether...
Thalidomide 4'-ether-alkylC2-amine hydrochloride is a synthesized E3 ligase ligand-linker conjugate.
-
Myosin Kinase Inhibi...
Myosin light chain kinase fragment 11-19 amide (MLCK(11-19) amide) is a substrate-specific peptide inhibitor of MLCK. Myosin light chain kinase fragment 11-19 amide inhibits hypotonicity-induced Ca2+ entry. Myosin light chain kinase fragment 11-19 amide can be used in the research of human cervical cancer.
